GlassScriptPhysician profile
Ji-Suk Moon
NPI 1952831133
$1,181.84
in general payments reported to CMS, 2019-2025
15 companies · $449 in 2025
The $449 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $50.32 · 2021: $83.64 · 2022: $153 · 2023: $314 · 2024: $23.85 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $785.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $303.03 | 2023-2025 | Impella |
| Mallinckrodt Hospital Products INC. | $172.86 | 2025 | Terlivaz |
| Janssen Pharmaceuticals, INC | $141.42 | 2020-2022 | |
| Amgen INC. | $121.86 | 2023 | Evenity |
| Haemonetics Corporation | $103.52 | 2025 | Teg6s Hemostasis System |
| Novo Nordisk INC | $95.08 | 2019 | |
| Novartis Pharmaceuticals Corporation | $84.62 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $34.90 | 2022-2023 | Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $32.30 | 2020-2022 | |
| Abbott Laboratories | $23.85 | 2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Merck Sharp & Dohme LLC | $15.89 | 2023 | Dificid, Zerbaxa |
| Astrazeneca Pharmaceuticals LP | $14.94 | 2023 | |
| Astellas Pharma US INC | $13.62 | 2019 | |
| Pfizer INC. | $12.75 | 2020 | |
| Daxor Corporation | $11.20 | 2025 | Bva-100 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ji-Suk Moon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.